Systematic evaluation of therapeutic effectiveness of Azvudine in treating COVID-19 hospitalized patients: a retrospective cohort study
BackgroundAzvudine, a repurposed oral small molecule antiviral drug, has potential effects in combating the SARS-CoV-2 virus. However, studies on its clinical efficacy in patients with COVID-19 are still limited and controversial, and further research and validation are necessary.MethodsA retrospect...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-11-01
|
| Series: | Frontiers in Cellular and Infection Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2024.1453234/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850199058327535616 |
|---|---|
| author | Yingkai Xu Yingkai Xu Yuan Huang Zihan Yuan Zihan Yuan Wanbing Liu Li Wang Lei Liu |
| author_facet | Yingkai Xu Yingkai Xu Yuan Huang Zihan Yuan Zihan Yuan Wanbing Liu Li Wang Lei Liu |
| author_sort | Yingkai Xu |
| collection | DOAJ |
| description | BackgroundAzvudine, a repurposed oral small molecule antiviral drug, has potential effects in combating the SARS-CoV-2 virus. However, studies on its clinical efficacy in patients with COVID-19 are still limited and controversial, and further research and validation are necessary.MethodsA retrospective cohort study was conducted on COVID-19 patients who were hospitalized in the General Hospital of Central Theater Command from 1 December 2022 to 31 January 2023. We included 132 patients treated with Azvudine and 132 controls after screening and propensity score matching. The primary outcomes including all-cause mortality and a composite outcome of disease progression such as non-invasive respiratory support, invasive respiratory support, admission to intensive care unit (ICU), and death were compared.ResultsAzvudine recipients had a much lower incidence rate of composite disease progression outcome than controls (13.9075/1000 person-days versus 25.7731/1000 person-days, P<0.05). Azvudine recipients also possessed a lower all-cause mortality rate than controls (2.6797/1000 person-days versus 8.5910/1000 person-days, P<0.01). Azvudine treatment significantly reduced the risk of composite disease progression (HR: 0.37, 95% CI: 0.16-0.84, P=0.017) and all-cause death (HR: 0.25, 95% CI: 0.08-0.81, P=0.021) after adjusting potential confounding factors such as age, sex, severity of COVID-19, complications, concomitant therapy, time from symptoms to treatment, and important laboratory indicators. The subgroup analyses of composite disease progression outcome and all-cause death indicated robustness of Azvudine’s in treating COVID-19 patients in general.ConclusionOur study demonstrates that Azvudine has a significant positive impact on the clinical recovery of hospitalized patients with COVID-19. These findings provide important support for the use of Azvudine as a therapeutic option for COVID-19, given the current divergent views on its therapeutic efficacy and its importance in public health and medical care. |
| format | Article |
| id | doaj-art-2ca0bba0526c41a2917078c0c43a63bf |
| institution | OA Journals |
| issn | 2235-2988 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cellular and Infection Microbiology |
| spelling | doaj-art-2ca0bba0526c41a2917078c0c43a63bf2025-08-20T02:12:42ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882024-11-011410.3389/fcimb.2024.14532341453234Systematic evaluation of therapeutic effectiveness of Azvudine in treating COVID-19 hospitalized patients: a retrospective cohort studyYingkai Xu0Yingkai Xu1Yuan Huang2Zihan Yuan3Zihan Yuan4Wanbing Liu5Li Wang6Lei Liu7Medical College, Wuhan University of Science and Technology, Wuhan, Hubei, ChinaDepartment of Transfusion Medicine; General Hospital of Central Theater Command, Wuhan, Hubei, ChinaDepartment of Gynaecology and Obstetrics; General Hospital of Central Theater Command, Wuhan, Hubei, ChinaMedical College, Wuhan University of Science and Technology, Wuhan, Hubei, ChinaDepartment of Transfusion Medicine; General Hospital of Central Theater Command, Wuhan, Hubei, ChinaDepartment of Transfusion Medicine; General Hospital of Central Theater Command, Wuhan, Hubei, ChinaDepartment of Clinical Laboratory, The First Affiliated Hospital of Henan University, Kaifeng, Henan, ChinaDepartment of Transfusion Medicine; General Hospital of Central Theater Command, Wuhan, Hubei, ChinaBackgroundAzvudine, a repurposed oral small molecule antiviral drug, has potential effects in combating the SARS-CoV-2 virus. However, studies on its clinical efficacy in patients with COVID-19 are still limited and controversial, and further research and validation are necessary.MethodsA retrospective cohort study was conducted on COVID-19 patients who were hospitalized in the General Hospital of Central Theater Command from 1 December 2022 to 31 January 2023. We included 132 patients treated with Azvudine and 132 controls after screening and propensity score matching. The primary outcomes including all-cause mortality and a composite outcome of disease progression such as non-invasive respiratory support, invasive respiratory support, admission to intensive care unit (ICU), and death were compared.ResultsAzvudine recipients had a much lower incidence rate of composite disease progression outcome than controls (13.9075/1000 person-days versus 25.7731/1000 person-days, P<0.05). Azvudine recipients also possessed a lower all-cause mortality rate than controls (2.6797/1000 person-days versus 8.5910/1000 person-days, P<0.01). Azvudine treatment significantly reduced the risk of composite disease progression (HR: 0.37, 95% CI: 0.16-0.84, P=0.017) and all-cause death (HR: 0.25, 95% CI: 0.08-0.81, P=0.021) after adjusting potential confounding factors such as age, sex, severity of COVID-19, complications, concomitant therapy, time from symptoms to treatment, and important laboratory indicators. The subgroup analyses of composite disease progression outcome and all-cause death indicated robustness of Azvudine’s in treating COVID-19 patients in general.ConclusionOur study demonstrates that Azvudine has a significant positive impact on the clinical recovery of hospitalized patients with COVID-19. These findings provide important support for the use of Azvudine as a therapeutic option for COVID-19, given the current divergent views on its therapeutic efficacy and its importance in public health and medical care.https://www.frontiersin.org/articles/10.3389/fcimb.2024.1453234/fullCOVID-19Azvudinecomposite disease progression outcomeall-cause deathretrospective cohort study |
| spellingShingle | Yingkai Xu Yingkai Xu Yuan Huang Zihan Yuan Zihan Yuan Wanbing Liu Li Wang Lei Liu Systematic evaluation of therapeutic effectiveness of Azvudine in treating COVID-19 hospitalized patients: a retrospective cohort study Frontiers in Cellular and Infection Microbiology COVID-19 Azvudine composite disease progression outcome all-cause death retrospective cohort study |
| title | Systematic evaluation of therapeutic effectiveness of Azvudine in treating COVID-19 hospitalized patients: a retrospective cohort study |
| title_full | Systematic evaluation of therapeutic effectiveness of Azvudine in treating COVID-19 hospitalized patients: a retrospective cohort study |
| title_fullStr | Systematic evaluation of therapeutic effectiveness of Azvudine in treating COVID-19 hospitalized patients: a retrospective cohort study |
| title_full_unstemmed | Systematic evaluation of therapeutic effectiveness of Azvudine in treating COVID-19 hospitalized patients: a retrospective cohort study |
| title_short | Systematic evaluation of therapeutic effectiveness of Azvudine in treating COVID-19 hospitalized patients: a retrospective cohort study |
| title_sort | systematic evaluation of therapeutic effectiveness of azvudine in treating covid 19 hospitalized patients a retrospective cohort study |
| topic | COVID-19 Azvudine composite disease progression outcome all-cause death retrospective cohort study |
| url | https://www.frontiersin.org/articles/10.3389/fcimb.2024.1453234/full |
| work_keys_str_mv | AT yingkaixu systematicevaluationoftherapeuticeffectivenessofazvudineintreatingcovid19hospitalizedpatientsaretrospectivecohortstudy AT yingkaixu systematicevaluationoftherapeuticeffectivenessofazvudineintreatingcovid19hospitalizedpatientsaretrospectivecohortstudy AT yuanhuang systematicevaluationoftherapeuticeffectivenessofazvudineintreatingcovid19hospitalizedpatientsaretrospectivecohortstudy AT zihanyuan systematicevaluationoftherapeuticeffectivenessofazvudineintreatingcovid19hospitalizedpatientsaretrospectivecohortstudy AT zihanyuan systematicevaluationoftherapeuticeffectivenessofazvudineintreatingcovid19hospitalizedpatientsaretrospectivecohortstudy AT wanbingliu systematicevaluationoftherapeuticeffectivenessofazvudineintreatingcovid19hospitalizedpatientsaretrospectivecohortstudy AT liwang systematicevaluationoftherapeuticeffectivenessofazvudineintreatingcovid19hospitalizedpatientsaretrospectivecohortstudy AT leiliu systematicevaluationoftherapeuticeffectivenessofazvudineintreatingcovid19hospitalizedpatientsaretrospectivecohortstudy |